Latest News
Research by BrightFocus grantee Matthew Campbell, PhD, of Trinity College Dublin, represents a potential new way to help clear the brain of a build-up of the toxic amyloid beta (Aβ) that leads to Alzheimer’s.
World Alzheimer’s Day finds us at a crossroads. We are confronted by a mounting global health and economic crisis. But we are also seeing encouraging signs from our laboratories, local communities, and halls of government.
Brian Elderton joins BrightFocus Foundation as Vice President for Development. He brings more than 25 years of senior leadership experience with higher education and health care institutions.
Seven BrightFocus grantees had their research chosen as a “Hot Topic” by the ARVO Scientific Program Committee. Read about their exciting work.
BrightFocus Foundation today announced that its 2015 research program grants have been awarded to 58 scientists in 20 states and 7 foreign countries. Part of an $11 million research investment, the grants reflect the largest annual research funding in the foundation’s history.
Download the summer edition of our Alzheimer's disease newsletter and learn about a cancer drug that shows early promise as an Alzheimer's treatment, a new drug that passes early clinical trial tests in humans, and other helpful information.
Download the summer 2015 issue of our macular degeneration newsletter to learn about a new AMD treatment that is close to human clinical trials, how cataract surgery affects AMD, AREDS vitamins. risk reduction strategies for AMD, and more.
Two BrightFocus grantees are honored by receiving the 2015 MetLife Foundation Awards in Medical Research, which work to stimulate novel investigations in the field of Alzheimer’s disease.
